加科思完成KRAS抑制剂JAB-23E73首例患者给药
财中社11月25日电加科思-B（01167）发布自愿公告，宣布其自主研发的泛KRAS抑制剂JAB-23E73在中国完成I/IIa期临床试验首例患者给药。KRAS突变广泛存在于多种肿瘤中，约23%-25%的癌症患者带有KRAS突变，全球每年新增约270万带有KRAS相关突变的肿瘤患者有望从这一抑制剂中获益。JAB-23E73具有良好的药代动力学特性，并能够同时抑制KRAS的活性及非活性状态。
公司致力于为患者提供突破性治疗方案，研发项目围绕KRAS、肿瘤免疫、肿瘤代谢等六大肿瘤信号通路布局，目标是成为全球认可的药物研发领导者。公司在北京、上海和波士顿设有实验室，并拥有诱导变构药物发现平台和免疫刺激性抗体偶联药物研发平台。尽管公司在研发方面取得进展，但仍无法确保JAB-23E73的成功开发及最终销售，股东及潜在投资者在交易时需谨慎。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10